Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB) and Dyne Therapeutics (DYN)
TipRanks (Mon, 27-Jul 8:30 AM ET)
PRNewswire (Wed, 22-Jul 4:05 PM ET)
Market Chameleon (Mon, 20-Jul 7:44 AM ET)
PRNewswire (Mon, 20-Jul 8:00 AM ET)
Market Chameleon (Tue, 7-Jul 5:40 AM ET)
PRNewswire (Mon, 6-Jul 5:11 PM ET)
PRNewswire (Mon, 29-Jun 8:00 AM ET)
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
PRNewswire (Thu, 25-Jun 11:59 PM ET)
Nuvation Bio Announces Proposed Convertible Senior Notes Offering
PRNewswire (Thu, 25-Jun 7:00 AM ET)
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
PRNewswire (Wed, 27-May 4:05 PM ET)
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Nuvation Bio Class A trades on the NYSE stock market under the symbol NUVB.
As of July 28, 2026, NUVB stock price declined to $6.53 with 1,798,742 million shares trading.
NUVB has a beta of 1.58, meaning it tends to be more sensitive to market movements. NUVB has a correlation of 0.05 to the broad based SPY ETF.
NUVB has a market cap of $2.24 billion. This is considered a Mid Cap stock.
Last quarter Nuvation Bio Class A reported $83 million in Revenue and $.01 earnings per share. This beat revenue expectation by $15 million and missed earnings estimates by -$.05.
In the last 3 years, NUVB traded as high as $9.75 and as low as $.95.
The top ETF exchange traded funds that NUVB belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
NUVB has outperformed the market in the last year with a price return of +161.2% while the SPY ETF gained +17.6%. NUVB has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +43.2% and +13.2%, respectively, while the SPY returned +3.9% and -1.0%, respectively.
NUVB support price is $6.36 and resistance is $6.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUVB shares will trade within this expected range on the day.
